Board of Directors

Dr. Sandra Panem

Dr. Panem has extensive experience in life science and healthcare venture capital.  She has been Managing Partner at Cross Atlantic Partners since 2000.  Previously, she was President of Vector Fund Management; Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund; and Vice President, Salomon Brothers Venture Capital.  Previously she was Science and Public Policy Fellow in economics studies at The Brookings Institution and assistant professor of pathology at the University of Chicago.  Dr. Panem received as B.S. in Biochemistry and a Ph.D. in Microbiology from the University of Chicago.
 
Dr. Panem has served on numerous public and private company Boards including Martek Biosciences (NASDAQ:MATK), IBAH Pharmaceuticals (IBAH), Confluent Surgical and Molecular Informatics.  She currently serves on the Boards of Acorda Therapeutics (NASDAQ:ACOR), MDx Medical (Vitals.com) and Labcyte.

Dr. Jean-Yves Nothias

Dr. Nothias leads the Biotechnology Team at Amundi Private Equity Funds. In addition to overseeing portfolio companies, he has made significant contributions by bringing in CEOs, syndicating financial rounds, and providing strategic advice. Previously, he was a biotechnology analyst for Paris-based Hambrecht & Quist. Dr. Nothias holds a PhD in molecular biology from Université Paris VI and a Masters Degree in Management from Université Paris Sorbonne.

Overseeing a global portfolio of 35 biotechnology investments, he is a board member of 2 US companies, GenomeQuest Inc. & Scynexis Inc and 5 French companies including Biosystems International, Genomic Vision, Ingen Biosciences, Ipsogen, and Trod Medical. Other private or public investments include Targacept (NASDAQ:TRGT), PTC Therapeutics, and Somalogic in the US and Trophos, Metabolic Explorer and Adocia in France.

Todd Pietri

Mr. Pietri co-founded Milestone Venture Partners, an early stage venture capital fund located in New York City which invests over half of its capital in digital healthcare companies.  Milestone was the first institutional lead investor in Medidata Solutions, Inc (NASDAQ:MDSO), which provides SaaS-based clinical development solutions that enhance the efficiency of clinical trials and had a successful IPO in 2009.  Including GenomeQuest, Mr. Pietri is currently responsible for five of Milestone’s digital health investments: Octagon Research Solutions, SmartAnalyst, MedPage Today, and MDX Medical ("Vitals.com"). 

Prior to Milestone, Mr. Pietri was an investment banker, a turn-around LBO firm investment professional, and a software company operating executive. Mr. Pietri’s operating experience spans direct sales, sales management, channel management, business development and business process consulting. Mr. Pietri received his BA (cum laude) in English from Duke University in 1989 and his MBA (valedictorian) from the Robinson School of Business at Georgia State University in 1997. He is also a CFA charterholder and a regular guest lecturer on venture capital at The Johnson School, Cornell University’s MBA program.

Ranjan Lal

Mr. Lal is the General Partner and manages the day-to-day activities of the Fund at Mosaix Ventures. Prior to founding Mosaix Ventures, Mr. Lal was a senior investment professional with Vector Fund Management and UBS O'Connor for eight years where his responsibilities included healthcare investing in private and public equities respectively. Prior to this, Mr. Lal worked in management consulting with McKinsey & Company for five years.

Mr. Lal received his MBA from the University of Chicago, and MS and BS in Mechanical Engineering from Pennsylvania State University and the Indian Institute of Technology, Roorkee respectively. Mr. Lal has served on numerous private companies Boards and currently serves as a Director with Argo Tea, ConsumerMed, GenomeQuest and KnowledgeAdvisors.

Mosaix exited investments include ACIST Medical (a medical device maker acquired by the Bracco Group), American WholeHealth Networks (a leading provider of integrative medicine services acquired by Axia Health Management, which subsequently merged with Healthways NASDAQ:HWAY) and Omnicell (a clinical automation provider).

Dick Fryling

Dick co-founded DOME Imaging Systems, Inc. in 1989, and served as its CEO until 2002, when it was acquired by Planar Systems, Inc. DOME was the leading provider of hardware and software products used to view and manipulate diagnostic-quality medical images on PCs and workstations, enabling the transition from film-based radiology to digital medical imaging. Based entirely on $2 million in early-stage equity financing by a group of individual angel investors (and a whole lot of sweat equity), DOME became a highly profitable company with over $40 million in annual revenues and returned over $70 million to its investors and founders.

Prior to starting DOME, Dick managed software product development teams, specializing in high-performance computer graphics, at Lotus and at Number Nine Computer. He has also worked at Tom Snyder Productions, developing educational game software. Dick's latest passion is DoInk, a Massachusetts startup integrating social networking, art, and animation.

Dick holds a Ph.D. in Political Science and an S.B. in Mathematics from the Massachusetts Institute of Technology.